Graybug to Present at the 2022 OIS Retina Innovation Summit
06 juil. 2022 07h15 HE
|
Graybug Vision, Inc.
BALTIMORE, July 06, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug Vision Appoints Dirk Sauer to Board of Directors
13 avr. 2022 16h05 HE
|
Graybug Vision, Inc.
BALTIMORE, April 13, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Graybug Vision to Participate in the 2021 Wedbush PacGrow Healthcare Virtual Conference
04 août 2021 07h30 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...
Graybug Vision Announces First Quarter 2021 Financial Results and Recent Corporate Developments
12 mai 2021 07h30 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...
Graybug Vision Reports Full-Data Analysis from 12-Month Treatment Phase of ALTISSIMO Phase 2b Trial in Wet AMD
12 mai 2021 07h00 HE
|
Graybug Vision, Inc.
GB-102 1mg has shown competitive durability and anatomical control versus afliberceptTrend in mean BCVA of GB-102 1mg compared to aflibercept driven primarily by a subgroup of patientsDeveloping...
Graybug Vision to Report Full-Data Analysis of the 12-month Treatment Phase of its Phase 2b ALTISSIMO Trial
05 mai 2021 16h05 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...
Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO Trial
09 mars 2021 07h30 HE
|
Graybug Vision, Inc.
Median time to first supportive therapy was 5 months for GB-102 1mg48% of patients in the GB-102 1 mg arm were rescue-free for at least 6 monthsControl of retinal thickness was consistent across all...
Graybug Vision Announces Full Year 2020 Financial Results and Recent Corporate Developments
04 mars 2021 17h04 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...
Graybug Vision to Participate in SVB Leerink Global Healthcare Conference
17 févr. 2021 07h30 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
Graybug Vision Appoints Bettina Maunz as Chief People Officer, Expanding the Company’s Executive Team
01 févr. 2021 07h30 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...